Glen Eagle Advisors, LLC Lineage Cell Therapeutics, Inc. Transaction History

Glen Eagle Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Aug 13, 2024	SELL	$1.84 - $2.68 $920 - $1,340	-500 Closed	0 $0
Q4 2020 Aug 13, 2024	BUY	$0.95 - $1.83 $475 - $915	500 New	500 $880,000
Q2 2020 Aug 13, 2024	SELL	$0.71 - $1.18 $435 - $723	-613 Reduced 55.08%	500 $435,000
Q1 2020 Aug 13, 2024	SELL	$0.6 - $1.58 $450 - $1,185	-750 Reduced 40.26%	1,113 $922,000
Q3 2019 Aug 13, 2024	BUY	$0.85 - $1.24 $1,583 - $2,310	1,863 New	1,863 $1.83 Million

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $88.3M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.